Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of p14ARF in HeLa cells using a p14ARF polyclonal antibody (Product # PA1-31409). Panel one is a brightfield image and panel two is an overlay of the brightfield image with immunofluorescent staining of p14RF detected using Dylight 488, showing nuclear localization of p14ARF staining.
|Tested species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to a portion of human p14ARF (between residues 50-150) .|
|Purification||Antigen affinity chromatography|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:400|
|Immunohistochemistry (Frozen) (IHC (F))||1:10-1:200|
|Immunohistochemistry (Paraffin) (IHC (P))||1:10-1:200|
|Western Blot (WB)||1:100-1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-31409 detects p14ARF from human samples.
PA1-31409 has been successfully used in immunofluorescence, Western blot applications.
The PA1-31409 immunogen is: Synthetic peptide corresponding to a portion of human p14ARF (between residues 50-150) .
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
IP-MS enrichment of CDKN2A (LFQ intensity): CDKN2A was enriched 768-fold from BT549 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and CDKN2A antibody (Part No. PA1-31409). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
alternative reading frame; ARF; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; cdkn2a; cell cycle negative regulator beta; CMM2; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; INK4; INK4a; mitochondrial smARF; MLM; MTS1; multiple tumor suppressor 1; p16; p16-INK4; p16-INK4a; p16INK4; p16INK4a; p19; p19Arf; TP16
ARF; ARF-INK4a; CDK4I; CDKN2; CDKN2A; CMM2; INK4; INK4A; INK4a-ARF; Ink4a/Arf; MLM; MTS-1; MTS1; P14; P14ARF; P16; p16(INK4a); P16-INK4A; P16INK4; P16INK4A; P19; p19<ARF>; P19ARF; Pctr1; TP16